Daymark Wealth Partners LLC Cuts Position in Zoetis Inc. (NYSE:ZTS)

Daymark Wealth Partners LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 2.9% in the fourth quarter, Holdings Channel reports. The fund owned 9,034 shares of the company’s stock after selling 273 shares during the period. Daymark Wealth Partners LLC’s holdings in Zoetis were worth $1,472,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at $31,000. First Personal Financial Services purchased a new position in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis in the third quarter valued at $33,000. Dunhill Financial LLC lifted its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP boosted its position in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $166.64 on Thursday. The firm has a market cap of $75.18 billion, a P/E ratio of 31.32, a P/E/G ratio of 2.58 and a beta of 0.89. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The business’s 50-day moving average price is $170.60 and its 200 day moving average price is $179.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the company posted $1.36 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, equities research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ZTS shares. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Finally, Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.